A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

• ClinicalTrials.gov Identifier: NCT01683279
• Recruitment Status: Active, not recruiting
• First Posted: September 11, 2012
• Last Update Posted: February 16, 2022
• Sponsor: Seattle Children's Hospital
• Information provided by (Responsible Party): Rebecca Gardner, Seattle Children's Hospital

Tracking Information

• First Submitted Date: September 7, 2012
• First Posted Date: September 11, 2012
• Last Update Posted Date: February 16, 2022
• Actual Study Start Date: March 25, 2012
• Actual Primary Completion Date: January 7, 2015 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 7, 2012)

Number of Participant with Adverse Events [ Time Frame: 42 days ]

The safety of the T cell infusion will be described and the maximum tolerated dose determined.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: September 7, 2012)

• Persistence of the CD19 CAR+ T cells [ Time Frame: 42 days ]
  Patients will be followed for 42 days to determine if the transferred T cells remain detectable in the blood and bone marrow
• Determine if there is anti-leukemic activity of the CD19 CAR+ T cells [ Time Frame: 42 days ]
  Patients will have their bone marrow assessed following the T cell infusion to determine if their disease responded to the treatment

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
• Official Title: Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor
• Brief Summary: Patients with relapsed leukemia often develop resistance to chemotherapy. For this reason, we are attempting to use a patient's own T cells, which can be genetically modified to expresses a chimeric antigen receptor(CAR). The CAR enables the T cell to recognize and kill the leukemic cells though the recognition of CD19, a protein expressed on the surface of the majority of pediatric ALL. This is a phase I study designed to determine the maximum tolerated dose of the CAR+ T cells and define the toxicity of the treatment. As a secondary aim, we will be looking at the efficacy of the T cells on eradicating the patient's leukemic cells.

Detailed Description

Upon meeting the eligibility requirements and enrolling on study, subjects will undergo a blood draw to obtain the T cells for the generation of the CD19 CAR+ T cells. The T cells are isolated from the blood, transduced with a lentivirus to express the CD19 CAR, and expanded in culture over a three week period. During the process of cell generation, subjects will continue to be cared for by their primary oncologist and may undergo additional treatment directed at the leukemia during this time.

After the CAR+ T cells have been generated, the subject undergoes a disease assessment and will be admitted to the hospital to receive 2 days of cyclophosphamide for lymphodepletion and reduction of disease burden. Several days later, the subject will receive an infusion of the CAR+ T cells.

Following treatment with the CAR+ T cells, subjects will be intensely followed for 6 weeks with serial blood testing and re-evaluation of disease status with bone marrow aspirates. After 6 weeks, the subjects clinical care will be resumed by their primary oncologist, and it is possible that they would receive additionally chemotherapy or a stem cell transplant.

Upon completion of the study, subjects will be followed at least annually with a either a medical history, physical exam and blood tests or a phone call/questionnaire for 15 years. This follow up will help to determine if the subject develops any long-term health problems related to the CAR+ T cells including a new cancer.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: B Cell Leukemia

Intervention

Biological: Autologous CD19 CAR+ EGFTt + T cells

Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag

Study Arms

Experimental: CAR+ T cells

Subjects will receive two days of cyclophosphamide for a total of 3g/m^2 followed several days later by a single dose of Autologous CD19 CAR+ EGFTt + T cells

Intervention: Biological: Autologous CD19 CAR+ EGFTt + T cells

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: January 31, 2019): 6
• Original Estimated Enrollment (submitted: September 7, 2012): 18
• Estimated Study Completion Date: January 7, 2030
• Actual Primary Completion Date: January 7, 2015 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• CD19+ Leukemia in 1st marrow relapse with MRD at the end of 1st month of re-induction
• CD19+ Leukemia in 2nd or greater relapse
• CD19+ Leukemia with indication for HCT, but has contraindication
• Age between 1 and 26 years of age
• Karnofsky of >50 or Lansky >50
• Life Expectancy >12 weeks
• Able to tolerate a blood draw of 4-6mL/kg
• Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
• absolute lymphocyte count of >/=750 cell/mm3 or >/=500 is >20kg
• creatinine clearance or radioisotope GFR >/= 70mL/min/1.73m2 OR normal serum creatinine based on age/gender
• total bilirubin </= 1.5x upper limit normal OR direct bilirubin </= 1.5mg/dl
• ALT </= 3x upper limit normal
• corrected QTc <450msec of ECG
• Shortening Fraction >28% by ECHO or Ejection Fraction >50% by MUGA
• Documented negative HIV, Hep B and Hep C
• Agree to long-term follow up for up to 15 years if they receive T cell infusion

Exclusion Criteria:

• Philadelphia Positive Leukemia
• Prior Allogeneic Stem Cell Transplant
• CNS 2 or 3
• prior cellular immunotherapy with chimeric antigen receptor modified T cells
• fully humanized antibodies within three half lives
• systemic corticosteroids within 7 days of enrollment
• requires supplemental oxygen or has a chest X-ray with an infectious process
• CNS pathology (seizure disorder, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder)
• Pregnant or breastfeeding women. Female participant of reproductive age must have a negative pregnancy test and agree to contraception for 1 year after T cell infusion.
• Active Malignancy other than CD19+ Leukemia
• Active severe infection defined as a positive blood culture within 48 hours of study enrollment or a fever >38.2C AND clinical signs of infection within 48 hours of study enrollment
• Patient has a concurrent medical condition, that in the opinion of the protocol PI or designee, would prevent the patient from undergoing protocol-based therapy.
• Trisomy 21
• Primary immunodeficiency/bone marrow failure syndrome

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 1 Year to 26 Years (Child, Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT01683279
• Other Study ID Numbers: PLAT-01
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Rebecca Gardner, Seattle Children's Hospital
• Original Responsible Party: Rebecca Gardner, Seattle Children's Hospital, Acting Assistant Professor
• Current Study Sponsor: Seattle Children's Hospital
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Chair: Rebecca Gardner, MD; Seattle Children's Hospital

• PRS Account: Seattle Children's Hospital
• Verification Date: February 2022